公司資料
BioXcel 股價、新聞與催化劑
- 股票代碼:
- BTAI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.07 USD (-37.11%)
收盤價
最後更新: 2026年9月4日
36.7M USD
市值
股價為何變動
目前無法取得 BTAI 的收盤價變動背景。
公司概覽
業務概覽
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
所在地與產業分類
BioXcel is headquartered in the United States and listed on NASDAQ. It sits in neuroscience and platform biotechnology.
商業模式特徵
The company depends on clinical progress, platform validation, and the ability to turn AI-enabled discovery into real therapeutic value. Investors watch data, safety, and pipeline prioritization.
生技產業定位
BioXcel occupies a platform-heavy neuroscience niche within biotech. The stock is driven by whether its AI-assisted approach can support a viable pipeline.
未來催化劑
- BioXcel’s catalysts are IGALMI and the neuroscience pipeline, plus any strategic update that clarifies the company’s commercial path. The market will care about whether the product base can stabilize.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。